Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.

  • Revenue in -- (TTM)--
  • Net income in --
  • Incorporated1966
  • Employees--
  • Location
    Roche Holding AGGrenzacherstr. 124BASEL 4058SwitzerlandCHE
  • Phone+41 9 732354295
  • Websitehttp://www.roche.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ROG:SWX since
Enterprise Therapeutics LtdDeal completed07 Oct 202007 Oct 2020Deal completed-5.54%96.58m
Inflazome LtdDeal completed21 Sep 202021 Sep 2020Deal completed-12.84%449.81m
Data delayed at least 15 minutes, as of Feb 25 2021 15:26 GMT.

Institutional shareholders

5.25%Per cent of shares held by top holders
HolderShares% Held
APG Asset Management NVas of 30 Sep 20202.10m1.31%
Canada Pension Plan Investment Boardas of 31 Mar 20201.49m0.93%
Schroder Investment Management Ltd.as of 30 Jun 2020777.39k0.49%
J.O. Hambro Capital Management Ltd.as of 31 Dec 2020743.12k0.46%
Wellington Management Co. LLPas of 31 Dec 2020654.54k0.41%
The Vanguard Group, Inc.as of 31 Jan 2021643.58k0.40%
RBC Global Asset Management (UK) Ltd.as of 30 Jun 2020591.68k0.37%
Credit Suisse Asset Management (Schweiz) AGas of 30 Jun 2020484.79k0.30%
S.W. Mitchell Capital LLPas of 31 Mar 2020464.57k0.29%
GQG Partners LLCas of 30 Jun 2020457.59k0.29%
More ▼
Data from 30 Apr 2020 - 31 Jan 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.